Original Article

A New Immunogenic Structure of Polyepitopic Fusion against Leishmania major: In Silico Study

Abstract

Background: The lack of complete protection against leishmaniasis and the challenges of anti-leishmaniasis drug treatment have made the treatment process more difficult. This study aimed to develop a new strategy for preparing a vaccine against cutaneous leishmaniasis using some of the antigenic proteins of the Leishmania parasite.
Methods: This study was carried out in 2022 at Shahid Chamran University of Ahvaz, Ahvaz, Iran. After preparing suitable epitopes of the Leishmania parasite and examining their antiparasitic properties, the process of making a fusion vaccine was performed and with the help of various bioinformatics tools, physicochemical and structural properties as well as immunological and simulation properties were studied and finally optimized. Construction and cloning were performed in the E.coli K12 system and finally, the docking process was performed with Toll-like receptors (TLRs), major histocompatibility complex I (MHC-I), and MHC-II receptors. With the help of selected epitopes of the Leishmania parasite, which had a high percentage of population coverage, a stable, antigenic, and non-allergenic chimeric vaccine was predicted.
Results: The results of the structural analysis of the TLR5\vaccine complex and simulation of its molecular dynamics showed a sufficiently stable binding. It also showed good potential for stimulation and production of active B cells and memory, as well as the potential for CD8+ T, CD4+ T cell production and development of Th2 and Th1-induced immune responses.
Conclusion: Computational results showed that the designed immunogenic structure has the potential to adequately stimulate cellular and humoral immune responses against Leishmania parasitic disease. As a result of evaluating the effectiveness of the candidate vaccine through in vivo and in vitro immunological tests, it can be suggested as a vaccine against Leishmania major.

1. Heydarpour F, Sari AA, Mohebali M, et al. Incidence and disability-adjusted life years (Dalys) attributable to leishmaniasis in Iran, 2013. Ethiop J Health Sci. 2016; 26: 381-388.
2. Polonio T, Efferth T. Leishmaniasis: drug resistance and natural products. Int J Mol Med. 2008; 22(3): 277-286.
3. Hodiamont CJ, Kager PA, Bart A, et al. Species-directed therapy for leishmaniasis in returning travelers: a comprehensive guide. PLoS Negl Trop Dis. 2014; 8(5):e2832.
4. Engwerda CR, Matlashewski G. Development of Leishmania vaccines in the era of visceral leishmaniasis elimination. Trans R Soc Trop Med Hyg. 2015; 109(7):423-4.
5. Vakili B, Eslami M, Hatam GR, et al. Immunoinformatics-aided design of a potential multi-epitope peptide vaccine against Leishmania infantum. Int J Biol Macromol. 2018; 120(Pt A): 1127-1139.
6. Chacko A, Joseph M, Feltis T, Morris SK. Case report: Successful treatment of cutaneous leishmaniasis with topical paramomycin in a child after treatment failure with systemic fluconazole. Am J Trop Med Hyg. 2016; 95(4):793-794.
7. Uzonna JE, Joyce KL, Scott P. Low dose Leishmania major promotes a transient T helper cell type 2 response that is down-regulated by interferon γ–producing CD8+ T cells. J Exp Med. 2004; 199(11):1559-66.
8. Herath S, Kropf P, Müller I. Cross‐talk between CD8+ and CD4+ T cells in experimental cutaneous leishmaniasis: CD8+ T cells are required for optimal IFN‐γ production by CD4+ T cells. Parasite Immunol. 2003; 25(11-12): 559-67.
9. Iborra S, Soto M, Carrión J, et al. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis. Vaccine. 2004; 22(29-30):3865-76.
10. Farajnia S, Mahboudi F, Ajdari S, et al. Alimohammadian, Mononuclear cells from patients recovered from cutaneous leishmaniasis respond to Leishmania major amastigote class I nuclease with a predominant Th1-like response. Clin Exp Immunol. 2005; 139(3): 498-505.
11. Méndez S, Gurunathan S, Kamhawi S, et al. The potency and durability of DNA-and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge. J Immunol. 2001; 166(8): 5122-5128.
12. Thomson SA, Khanna R, Gardner J, et al. Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: implications for vaccine design. Proc Natl Acad Sci U S A. 1995; 92(13): 5845-5849.
13. Jain K, Jain NK. Vaccines for visceral leishmaniasis: A review. J Immunol Methods. 2015; 422: 1-12.
14. Kar T, Narsaria U, Basak S, et al. A candidate multi-epitope vaccine against SARS-CoV-2. Sci Rep. 2020; 10(1): 10895.
15. Atapour A, Mokarram P, MostafaviPour Z, et al. Designing a fusion protein vaccine against HCV: an in silico approach. Int J Pept Res Ther. 2019; 25: 861-872.
16. Gradoni L, Soteriadou K, Louzir H, et al. Drug regimens for visceral leishmaniasis in Mediterranean countries. Trop Med Int Health. 2008; 13(10):1272-6.
17. Ghorbani M, Farhoudi R. Leishmaniasis in humans: drug or vaccine therapy? Drug Des Devel Ther. 2017;12:25-40.
18. Ponte-Sucre A, Gamarro F, Dujardin JC, et al. Drug resistance and treatment failure in leishmaniasis: A 21st century challenge. PLoS Negl Trop Dis. 2017; 11(12): e0006052.
19. Oli AN, Obialor WO, Ifeanyichukwu MO, et al. Immunoinformatics and vaccine development: an overview. Immunotargets Ther. 2020; 9:13-30.
20. Mahboobi M, Sedighian H, Malekara E, et al. Harnessing an integrative in silico approach to engage highly immunogenic peptides in an antigen design against epsilon toxin (ETX) of Clostridium perfringens. Int J Pept Res Ther. 2021; 27: 1019-1026.
21. Irvine DJ, Read BJ. Shaping humoral immunity to vaccines through antigen-displaying nanoparticles. Curr Opin Immunol. 2020; 65: 1-6.
22. Agallou M, Margaroni M, Kotsakis SD, et al. A canine-directed chimeric multi-epitope vaccine induced protective immune responses in BALB/c Mice infected with Leishmania infantum. Vaccines (Basel). 2020; 8(3): 350.
23. María RR, Arturo CJ, Alicia JA, et al. The impact of bioinformatics on vaccine design and development. Vaccines. 2017; 2: 3-6.
24. Khatoon N, Pandey RK, Prajapati VK. Exploring Leishmania secretory proteins to design B and T cell multi-epitope subunit vaccine using immunoinformatics approach. Sci Rep. 2017; 7: 8285.
25. Khan MA, Ami JQ, Faisal K, et al. An immunoinformatic approach driven by experimental proteomics: in silico design of a subunit candidate vaccine targeting secretory proteins of Leishmania donovani amastigotes. Parasit Vectors. 2020; 13(1): 196.
Files
IssueVol 19 No 3 (2024) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijpa.v19i3.16387
Keywords
Leishmania Chimeric vaccine Bioinformatics Immunogenicity
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Pirmoradi S, Darvish Khadem M, Monjezi Z, Bahrami S, O. Nzelu C. A New Immunogenic Structure of Polyepitopic Fusion against Leishmania major: In Silico Study. Iran J Parasitol. 2024;19(3):290-304.